Genmab AS/Johnson & Johnson's anti-CD38 antibody Darzalex is now poised for a broader role as part of a combination regimen in frontline treatment of multiple myeloma, following a top-line release of positive Phase III data from the ALCYONE study, which was stopped early due to the efficacy findings.
Darzalex (daratumumab) initially was approved in November 2015 as a monotherapy for patients who have had three prior lines of...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)